Cassava Sciences Files 8-K/A Amendment
Ticker: FLNA · Form: 8-K/A · Filed: Dec 22, 2025 · CIK: 1069530
Sentiment: neutral
Topics: amendment, director-changes, officer-compensation
TL;DR
Cassava Sciences amended its 8-K, updating director and officer info.
AI Summary
Cassava Sciences, Inc. filed an 8-K/A on December 22, 2025, to amend a previous filing regarding events that occurred on October 21, 2025. The amendment pertains to the departure of a director, election of a new director, and compensatory arrangements for certain officers. The company is incorporated in Delaware and its principal business address is in Austin, Texas.
Why It Matters
This filing indicates changes in the company's board of directors and executive compensation structure, which can impact corporate governance and investor confidence.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and does not introduce new material financial or operational information.
Key Players & Entities
- Cassava Sciences, Inc. (company) — Registrant
- October 21, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Austin, Texas (location) — Business address
FAQ
What is the primary purpose of this 8-K/A filing?
The primary purpose is to amend a previous report concerning the departure of a director, election of a director, and compensatory arrangements for certain officers.
When was the earliest event reported in this filing?
The earliest event reported occurred on October 21, 2025.
What is Cassava Sciences, Inc.'s state of incorporation?
Cassava Sciences, Inc. is incorporated in Delaware.
Where is Cassava Sciences, Inc. located?
The company's business address is 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, Texas 78731.
What form type is this filing?
This filing is a Form 8-K/A, which is a Current Report.
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-12-22 16:09:39
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value SAVA NASDAQ Capital Market
Filing Documents
- sava20251219_8ka.htm (8-K/A) — 30KB
- 0001437749-25-038544.txt ( ) — 161KB
- sava-20251021.xsd (EX-101.SCH) — 3KB
- sava-20251021_def.xml (EX-101.DEF) — 12KB
- sava-20251021_lab.xml (EX-101.LAB) — 15KB
- sava-20251021_pre.xml (EX-101.PRE) — 12KB
- sava20251219_8ka_htm.xml (XML) — 3KB
From the Filing
sava20251219_8ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 21, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-41905 91-1911336 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 6801 N Capital of Texas Highway, Building 1; Suite 300 Austin , Texas 78731 (Address of principal executive offices, including zip code) ( 512 ) 501-2444 (Registrant ' s telephone number, including area code) (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below): Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b)) Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock , $0.001 par value SAVA NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Cassava Sciences, Inc. (the "Company") filed a Current Report on Form 8-K on October 22, 2025 (the "Form 8-K") to report the appointment of Dawn C. Bir to the Company's Board of Directors (the "Board"). At the time the Form 8-K was filed, the Board had not yet made a determination regarding Board committee assignments for Ms. Bir. The Form 8-K is hereby amended solely to report that on December 18, 2025, the Board appointed Ms. Bir as a member of the Board's Compensation Committee, effective as of such date. 9.01: Financial Statements and Exhibits The following exhibits are being furnished as part of this report. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CASSAVA SCIENCES, INC. a Delaware corporation Date: December 22, 2025 By: /s/ ERIC J. SCHOEN Eric J. Schoen Chief Financial Officer